- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05224778
DMCRN-02-001 : Évaluation des paramètres pédiatriques dans DM1 (ASPIRE-DM1)
Évaluation des paramètres pédiatriques dans DM1 (ASPIRE-DM1)
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Myotonic dystrophy type-1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3'UTR of the DMPK gene. DM1 is the most common adult-onset muscular dystrophy, with an overall prevalence of 1:8000. In approximately 10-20% of individuals with DM1, the onset of symptoms occurs at birth, which is known as congenital myotonic dystrophy (CDM).
Previous studies have enrolled a very limited number of children with CDM.
The rationale for this study is to include a larger population of patients with CDM in order to determine developmental milestones, measures of physical and cognitive function and quality of life, and correlate functional outcome measures with potential biomarkers in CDM .
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ruby Langeslay
- Numéro de téléphone: 804-828-8481
- E-mail: ruby.langeslay@vcuhealth.org
Sauvegarde des contacts de l'étude
- Nom: Jennifer Raymond
- Numéro de téléphone: 804-828-6318
- E-mail: jennifer.raymond@vcuhealth.org
Lieux d'étude
-
-
-
Milan, Italie, 20162
- Recrutement
- Centro Clinico NeMO
-
Contact:
- Michela Nani
- E-mail: michela.nani@centrocliniconemo.it
-
Contact:
- Luca Mauro
- E-mail: luca.mauro@centrocliniconemo.it
-
Chercheur principal:
- Valeria Sansone, MD
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- University of California, Los Angeles
-
Contact:
- Merve Kaleli
- E-mail: MKaleli@mednet.ucla.edu
-
Chercheur principal:
- Perry Shieh, MD, PhD
-
Contact:
- Dennis Fernando
- Numéro de téléphone: 310-825-3264
- E-mail: DeFernando@mednet.ucla.edu
-
-
Kansas
-
Fairway, Kansas, États-Unis, 66205
- Recrutement
- University of Kansas Medical Center
-
Chercheur principal:
- Jeffrey Statland, MD
-
Contact:
- Michaela Walker
- E-mail: mwalker20@kumc.edu
-
Contact:
- Cassidy Nelson
- E-mail: cnelson15@kumc.edu
-
-
New York
-
Rochester, New York, États-Unis, 14642
- Recrutement
- University of Rochester Medical Center
-
Contact:
- Jim Hilbert
- E-mail: james_hilbert@urmc.rochester.edu
-
Contact:
- Jeanne Dekdebrun
- E-mail: jeanne_dekdebrun@urmc.rochester.edu
-
Chercheur principal:
- Bohoon Lee, MD
-
-
Virginia
-
Richmond, Virginia, États-Unis, 23298
- Recrutement
- Virginia Commonwealth University
-
Contact:
- Shantel Kyles
- E-mail: shantel.brown@vcuhealth.org
-
Chercheur principal:
- Nicholas E. Johnson, MD
-
Contact:
- Jodie Howell
- E-mail: jodie.howell@vcuhealth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
30 children with CDM
La description
Inclusion Criteria:
- Age neonate to 3 years 11 months at enrollment.
- A diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500).
- Guardian is willing and able to sign consent and follow study procedures
Exclusion Criteria:
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of the site investigator
- Significant trauma within one month
- Internal metal or devices (exclusion for DEXA component)
- History of bleeding disorder or platelet count <50,000
- History of reaction to local anesthetic
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Congenital Myotonic Dystrophy (CDM)
CDM group includes those aged neonate to 3 years, 11 months at enrollment. Individuals must have a diagnosis of CDM, which is defined as children having symptoms of myotonic dystrophy in the newborn period (<30 days), such as hypotonia, feeding or respiratory difficulty, requiring hospitalization to a ward or to the neonatal intensive care unit for more than 72 hours; and a genetic test confirming an expanded trinucleotide (CTG) repeat in the DMPK gene in the child or mother. An expanded CTG repeat size in the child is considered greater than 200 repeats or E1-E4 classification (E1= 200-500, E2=500-1,000, E3=1,000-1,500, E4>1,500). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate motor milestone attainment in individuals with CDM and ChDM and compare to typically developing children
Délai: Through study completion at 18 months
|
Milestone Assessment using Peabody definitions: This survey would ask parents to assess the age of motor milestones in days, months of infant age. Birth history, including prematurity, ventilatory status, and feeding problems would also be collected on the CRF. Feeding and ventilatory support, as well as height and weight will be collected at each study visit. |
Through study completion at 18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dysarthria Assessment
Délai: Through study completion at 18 months
|
A blinded, standardized video assessment tabulating language milestones by a trained rater will be conducted at each visit. |
Through study completion at 18 months
|
|
Vineland
Délai: Through study completion at 18 months
|
The Vineland will be administered by an interviewer to ensure standardized intake of data. This assessment will capture the adaptive function, including gross motor and fine motor, as reported by the parent proxy. |
Through study completion at 18 months
|
|
CCMDHI
Délai: Through study completion at 18 months
|
The congenital and childhood myotonic dystrophy health index is a disease specific patient or proxy reported outcome measure specific to these conditions. The current study will utilize the proxy version. |
Through study completion at 18 months
|
|
Domain Delta
Délai: Through study completion at 18 months
|
This assessment asks parents for global impression of change related to the baseline visit and will be used as an anchoring measure for the statistical analyses. |
Through study completion at 18 months
|
|
Gross Motor Function Measure (GMFM-88)
Délai: Through study completion 18 months
|
The GMFM assesses functional abilities like lying/rolling, sitting, crawling/kneeling, standing, and walking, running, and jumping. |
Through study completion 18 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Correlate the functional outcome measures with potential biomarkers in CDM.
Délai: Baseline
|
Fine needle muscle biopsy:On the baseline visit, a fine needle aspirate will be performed. Biopsy will only be peformed once to minimize the risk. The procedure will be performed with local anesthesia (1% lidocaine without epinephrine and free of preservatives) of the vastus lateralis. Following lidocaine injection, a fine needle will be used to aspirate the quadriceps muscle to obtain a total of one aspirate. The aspirate will be flash frozen in liquid nitrogen. A similar procedure has been performed on adults with DM1, and the average biopsy yields sufficient tissue for RNA-Seq analysis. |
Baseline
|
|
Blood Sampling
Délai: Baseline, month 12, month 18
|
DNA and RNA samples will be processed by Virginia Commonwealth University. |
Baseline, month 12, month 18
|
|
Muscle mass, DEXA
Délai: Baseline, month 12, month 18
|
Lean muscle mass will be evaluated using serial DEXA scans as an exploratory endpoint. All sites will use a Hologic DEXA scanner. Investigators will evaluate whole body lean mass, left and right arm lean mass, and left and right leg lean mass. Particularly early in childhood, investigators would expect rapid changes in lean muscle mass. If there were a divergence between controls and subjects with CDM, this would provide evidence that CDM is a disorder of muscle maturity, as well as provide a potential biomarker. |
Baseline, month 12, month 18
|
|
World Health Organization (WHO) Motor Milestones
Délai: Through study completion at 18 months
|
The WHO Motor Milestones is a set of 6 standardized motor milestones that include 1) Sitting without support, 2) Standing with assistance, 3) Hands-&-knees crawling, 4) Walking with assistance, 5) Standing alone, and 6) Walking alone. |
Through study completion at 18 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Nicholas E. Johnson, MD, Virginia Commonwealth University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies musculo-squelettiques
- Maladies du système nerveux
- Maladies musculaires
- Maladies neuromusculaires
- Maladies génétiques, innées
- Maladies neurodégénératives
- Troubles hérédodégénératifs, système nerveux
- Troubles musculaires atrophiques
- Dystrophies musculaires
- Troubles myotoniques
- Maladies et anomalies congénitales, héréditaires et néonatales
- Dystrophie myotonique
Autres numéros d'identification d'étude
- HM20023386
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .